Education
About Us
Working with TipRanks
Follow Us
BioStem Technologies (BSEM)
:BSEM
BSEM Stock Chart & Stats
$4.83
$0.88(5.85%)
At close: 4:00 PM EST
$4.83
$0.88(5.85%)
Day’s Range― - ―
52-Week Range$3.09 - $19.28
Previous CloseN/A
Volume47.30K
Average Volume (3M)66.82K
Market Cap
$69.27M
Enterprise Value$85.20M
Total Cash (Recent Filing)$30.84M
Total Debt (Recent Filing)$3.59M
Price to Earnings (P/E)5.0
Beta1.88
Next Earnings
Apr 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding16,338,436
10 Day Avg. Volume61,192
30 Day Avg. Volume66,816
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.54
Price to Sales (P/S)0.75
P/FCF Ratio9.42
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit0.29
Enterprise Value/Ebitda3.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies’s price range in the past 12 months?
BioStem Technologies lowest stock price was $3.09 and its highest was $19.28 in the past 12 months.
What is BioStem Technologies’s market cap?
BioStem Technologies’s market cap is $69.27M.
When is BioStem Technologies’s upcoming earnings report date?
BioStem Technologies’s upcoming earnings report date is Apr 06, 2026 which is in 106 days.
How were BioStem Technologies’s earnings last quarter?
BioStem Technologies released its earnings results on Nov 13, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0 by $0.03.
Is BioStem Technologies overvalued?
According to Wall Street analysts BioStem Technologies’s price is currently Overvalued.
Does BioStem Technologies pay dividends?
BioStem Technologies does not currently pay dividends.
What is BioStem Technologies’s EPS estimate?
BioStem Technologies’s EPS estimate is 0.02.
How many shares outstanding does BioStem Technologies have?
BioStem Technologies has 16,338,436 shares outstanding.
What happened to BioStem Technologies’s price movement after its last earnings report?
BioStem Technologies reported an EPS of $0.03 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went down -3.865%.
Which hedge fund is a major shareholder of BioStem Technologies?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
BSEM Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.50%
12-Months-Change
Fundamentals
Return on Equity
55.46%
Trailing 12-Months
Asset Growth
-40.12%
Trailing 12-Months
Company Description
BioStem Technologies
BioStem Technologies (BSEM) is a biotechnology company focused on advancing regenerative medicine and cellular therapy. The company specializes in developing innovative solutions for tissue repair and regeneration, leveraging its proprietary processes for the extraction and application of stem cells derived from various biological sources. BSEM operates primarily in the healthcare sector, offering a range of products and services that cater to both clinical and research applications, including stem cell storage, processing, and therapeutic treatments.
BSEM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
BioStem Technologies demonstrated resilience and strategic growth through increased product volume, consistent positive adjusted EBITDA, and strong gross margins. The company successfully expanded into new markets despite facing revenue and cash balance declines due to competitive pricing pressures and strategic investments.View all BSEM earnings summariesTechnical Analysis
Crescent Biopharma
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Innate Pharma
―